Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus TETRACYN.
TETRACHEL vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic